BIVICTRIX THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13 GBX | 0.00% |
|
+4.00% | +23.81% |
| Jun. 21 | BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jun. 13 | EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 19.5 | 11.24 | 8.665 |
| Enterprise Value (EV) 1 | 13.69 | 8.248 | 5.648 |
| P/E ratio | -4.9 x | -4.5 x | -3 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -9,216,824 x | -2,817,758 x | -1,904,971 x |
| EV / FCF | -9,289,545 x | -3,760,223 x | -4,322,770 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 3.08 x | 2.84 x | 2.45 x |
| Nbr of stocks (in thousands) | 66,115 | 66,115 | 82,526 |
| Reference price 2 | 0.2950 | 0.1700 | 0.1050 |
| Announcement Date | 3/9/22 | 3/30/23 | 6/21/24 |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | -0.5201 | -1.485 | -2.927 | -2.965 |
| EBIT 1 | -0.48 | -0.526 | -0.5211 | -1.502 | -2.975 | -3.025 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.48 | -0.526 | -0.509 | -2.532 | -2.971 | -3.003 |
| Net income 1 | -0.378 | -0.409 | -0.425 | -2.34 | -2.497 | -2.545 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -4.634 | -4.274 | -4.022 | -0.0602 | -0.0378 | -0.0350 |
| Free Cash Flow | - | -0.2768 | -0.1585 | -1.473 | -2.193 | -1.307 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/5/21 | 8/5/21 | 8/5/21 | 3/9/22 | 3/30/23 | 6/21/24 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.21 | 0.13 | 0.19 | 5.82 | 2.99 | 3.02 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -0.28 | -0.16 | -1.47 | -2.19 | -1.31 |
| ROE (net income / shareholders' equity) | - | -167% | -344% | -73.2% | -48.6% | -67.9% |
| ROA (Net income/ Total Assets) | - | -107% | -48.8% | -23.6% | -32.6% | -42.8% |
| Assets 1 | - | 0.3819 | 0.8704 | 9.907 | 7.666 | 5.944 |
| Book Value Per Share 2 | 3.800 | 1.880 | 0 | 0.1000 | 0.0600 | 0.0400 |
| Cash Flow per Share 2 | 2.590 | 1.350 | 0.0300 | 0.0900 | 0.0500 | 0.0400 |
| Capex | - | - | 0.06 | 0.05 | 0.39 | 0.01 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 8/5/21 | 8/5/21 | 8/5/21 | 3/9/22 | 3/30/23 | 6/21/24 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.13
GBP
Average target price
0.66
GBP
Spread / Average Target
+407.69%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.81% | 13.71M | |
| +16.71% | 44.48B | |
| +43.74% | 40.57B | |
| -7.92% | 38.82B | |
| +33.09% | 32.22B | |
| -7.10% | 27.84B | |
| +14.46% | 26.79B | |
| +46.73% | 14.31B | |
| +34.07% | 12.7B | |
| -7.61% | 11.23B |
- Stock Market
- Equities
- BVX Stock
- Financials BiVictriX Therapeutics plc
